Jiangsu Hengrui Medicine
600276.SS
#469
Rank
A$65.77 B
Marketcap
$10.31
Share price
-1.60%
Change (1 day)
8.32%
Change (1 year)
Jiangsu Hengrui Medicine Company Limited is a Chinese pharmaceutical company engaged in the R&D, manufacturing and sales of healthcare products, including antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents and antibiotics

EPS for Jiangsu Hengrui Medicine (600276.SS)

EPS in 2023 (TTM): $0.14

According to Jiangsu Hengrui Medicine 's latest financial reports the company's current EPS (TTM) is $0.14. In 2022 the company made an earnings per share (EPS) of $0.14 a decrease over its 2021 EPS that were of $0.17.

EPS history for Jiangsu Hengrui Medicine from 2002 to 2023

Annual EPS

Year EPS Change
2023 (TTM)$0.14-3.88%
2022$0.14-17.1%
2021$0.17-24.44%
2020$0.2320.3%
2019$0.1925.58%
2018$0.1527.55%
2017$0.1221.64%
2016$0.0968313.57%
2015$0.0852639.86%
2014$0.0609621.33%
2013$0.0502417.7%
2012$0.0426925.56%
2011$0.0340026.22%
2010$0.0269310.3%
2009$0.0244257.92%
2008$0.0154611.06%
2007$0.0139285.81%
2006$0.00749387.94%
2005$0.00398733.97%
2004$0.00297629.78%
2003$0.00229319.78%
2002$0.001914